相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial
J. Bruix et al.
ANNALS OF ONCOLOGY (2016)
Increased Tumor Response to Neoadjuvant Therapy Among Rectal Cancer Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers
Zachary S. Morris et al.
CANCER (2016)
Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials
Michael J. Sorich et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?
Ellen Pure et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Cancer and liver cirrhosis: implications on prognosis and management
Matthias Pinter et al.
ESMO OPEN (2016)
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma
H. Izzedine et al.
ANNALS OF ONCOLOGY (2015)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma
E. Januel et al.
EUROPEAN JOURNAL OF NEUROLOGY (2015)
Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients
Antonio Facciorusso et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors
Won Sohn et al.
JOURNAL OF HEPATOLOGY (2015)
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
et al.
JOURNAL OF HEPATOLOGY (2015)
The Role of Mechanical Forces in Tumor Growth and Therapy
Rakesh K. Jain et al.
ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 16 (2014)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2014)
Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice
Magda Nasr et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Differential Effects of Sorafenib on Liver Versus Tumor Fibrosis Mediated by Stromal-Derived Factor 1 Alpha/C-X-C Receptor Type 4 Axis and Myeloid Differentiation Antigen-Positive Myeloid Cell Infiltration in Mice
Yunching Chen et al.
HEPATOLOGY (2014)
Fibroblast heterogeneity in the cancer wound
Daniel Oehlund et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis
Hitoshi Yoshiji et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma
Jung Il Lee et al.
JOURNAL OF HEPATOLOGY (2014)
Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team
Jessica Dyson et al.
JOURNAL OF HEPATOLOGY (2014)
Angiotensin-converting enzyme and the tumor microenvironment: mechanisms beyond angiogenesis
Derick Okwan-Duodu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2013)
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Rakesh K. Jain
JOURNAL OF CLINICAL ONCOLOGY (2013)
Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis
Yosui Tamaki et al.
JOURNAL OF GASTROENTEROLOGY (2013)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Vikash P. Chauhan et al.
NATURE COMMUNICATIONS (2013)
The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration
Jennifer Watt et al.
ONCOIMMUNOLOGY (2013)
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study
M. Pinter et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
A. Hollebecque et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
M. Pinter et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins
Young Kwang Chae et al.
CANCER INVESTIGATION (2011)
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination
Daniel Keizman et al.
EUROPEAN JOURNAL OF CANCER (2011)
Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program?
Florian Hucke et al.
WIENER KLINISCHE WOCHENSCHRIFT (2011)
Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine
Y. Nakai et al.
BRITISH JOURNAL OF CANCER (2010)
Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma
Andreia Hanada Otake et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Ghrelin Attenuates Hepatocellular Injury and Liver Fibrogenesis in Rodents and Influences Fibrosis Progression in Humans
Montserrat Moreno et al.
HEPATOLOGY (2010)
Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats
Hitoshi Yoshiji et al.
JOURNAL OF GASTROENTEROLOGY (2010)
Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis
Puneeta Tandon et al.
JOURNAL OF HEPATOLOGY (2010)
The renin-angiotensin system and cancer: old dog, new tricks
Amee J. George et al.
NATURE REVIEWS CANCER (2010)
Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression
Yuichiro Ohnuma et al.
BIOMEDICINE & PHARMACOTHERAPY (2009)
Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy
Stefan Wilop et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma
Hitoshi Yoshiji et al.
JOURNAL OF HEPATOLOGY (2009)
Angiogenesis in liver disease
Mercedes Fernandez et al.
JOURNAL OF HEPATOLOGY (2009)
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C
Kathleen E. Corey et al.
LIVER INTERNATIONAL (2009)
The renin-angiotensin system and malignancy
Eleanor I. Ager et al.
CARCINOGENESIS (2008)
Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
Yujin Hoshida et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
AT1 receptor antagonist Candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers
Wilma Debernardi-Venon et al.
JOURNAL OF HEPATOLOGY (2007)
Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression
H Yoshiji et al.
JOURNAL OF HEPATOLOGY (2005)
Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth
M Fujita et al.
CARCINOGENESIS (2005)
Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation
A Rimola et al.
TRANSPLANTATION (2004)
Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C
Y Terui et al.
HEPATOLOGY (2002)
Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats
H Yoshiji et al.
JOURNAL OF HEPATOLOGY (2002)
Angiotensin-II type I receptor interaction is a major regulator for liver fibrosis development in rats
H Yoshiji et al.
HEPATOLOGY (2001)
Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis
G Paizis et al.
JOURNAL OF HEPATOLOGY (2001)
Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis
J González-Abraldes et al.
GASTROENTEROLOGY (2001)
Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis
JR Jonsson et al.
GASTROENTEROLOGY (2001)
Angiotensin II induces contraction and proliferation of human hepatic stellate cells
R Bataller et al.
GASTROENTEROLOGY (2000)
分享论文
